Please note that IPD sharing statement and summary results sections will be added to the ANZCTR form in the coming weeks in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Trial ID
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
Scientific title
A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Study type
Description of intervention(s) / exposure
Treatment: Drugs - Azacitidine

Treatment: Drugs: Azacitidine

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Overall response rate
Timepoint [1] 0 0
Secondary outcome [1] 0 0
time to progression
Timepoint [1] 0 0
Secondary outcome [2] 0 0
duration of response
Timepoint [2] 0 0
Secondary outcome [3] 0 0
number of cycles of azacitidine required to first achieve a response
Timepoint [3] 0 0
Secondary outcome [4] 0 0
progression free survival
Timepoint [4] 0 0
Secondary outcome [5] 0 0
Timepoint [5] 0 0
Secondary outcome [6] 0 0
Timepoint [6] 0 0

Key inclusion criteria
- diagnosis of MM as per IMWG criteria

- age greater than 17 years

- have received at least 2 but no more than 4 prior lines of therapy

- have failed to respond to the most recently administered anti-MM therapy or have
demonstrably progressive disease as defined by accepted standard criteria

- have a life expectancy of at least 3 months

- ECOG performance status < 3

- at registration haematological values within the following limits:

1. absolute neutrophil count (ANC) > 1.0 x 109/L

2. platelet count > 50 x 109/L unsupported

- At registration biochemical values within the following limits

1. Bilirubin < 1.5 x upper limit of normal (ULN) and transaminases < 2 x ULN unless
considered secondary to hepatic myelomatous infiltration

2. Serum creatinine < 0.19mMol/L

- Written informed consent

- Must agree to use adequate contraceptive measures if indicated. Specifically, women of
childbearing potential (WOCBP) may participate provided they meet the following

1. Agree to use at least 2 effective contraceptive methods throughout the study and
for 30 days following the study

2. Have a negative serum pregnancy test within 24 hours of commencing on study

3. Male participants with female partners that are WOCBP must agree to use 2
effective contraceptive methods throughout the study and for 30 days following
the study
Minimum age
17 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Patients with monoclonal gammopathy of undetermined significance (MGUS) or
indolent/smouldering MM

- Known or suspected hypersensitivity to AZA or mannitol

- Patients whose general condition makes them unsuitable for intensive treatment e.g.
significant cardiac or pulmonary disease

- Active infections or other illnesses that precludes chemotherapy administration or
patient compliance

- Active viral infection with known human immunodeficiency virus (HIV) or viral
hepatitis type B or C

- Pregnant or lactating women

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Bayside Health

Ethics approval
Ethics application status

Brief summary
This is a Phase II trial evaluating the overall response rate, safety and tolerability to
azacitidine in patients with relapsed or refractory multiple myeloma.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Andrew Spencer, Assoc. Prof
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries